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1. ABSTRACT 
 
Epilepsy represents one of the most common chronic brain diseases affecting more 
than 50 million people worldwide. The current available antiepileptic drugs (AEDs) present 
multiple mechanisms of action whether they are direct or indirect, exerting their function in 
modulating several ion channels. The most common channels implicated are GABAA-receptors, 
voltage-gated sodium channels (VGSC), voltage-gated potassium channels (VGKC), high-
voltage-gated calcium channels (HVGCC) and AMPA receptor. Actelion Pharmaceuticals targeted 
another type of ion channel whose threshold was low, differing from the classical HVGCC: T-
type calcium channels (TTCCs). These low-threshold activation channels are products of 
different genes in mammals, being CACNA1H the most relevant in epileptogenesis. The 
unclassified epilepsies are categorised by ‘idiopathic', and there is a strong bond between 
genetic variation in the T-type calcium channel gene CACNA1H and idiopathic generalised 
epilepsies (IGEs). The different TTCCs are Cav3.1, Cav3.2 (CACNA1H) and Cav3.3, whose role in 
neuronal excitability and muscle contraction is crucial. However, these calcium antagonists have 
traditionally been used for the treatment of cardiovascular diseases, and further optimisation of 
their poor specificity led to a promising biological activity toward the Cav3 channel for epilepsy 
treatment. Currently, there are approximately 28 AEDs commercially available to patients, 
however, due to the diverse physiological and pathological processes implicated in this brain 
disorder, more than 30% of epileptic patients are pharmacoresistant to therapy and thus, 
unable to achieve seizure control. Despite the plethora of the approved AEDs, there is likely a 
limited number of actual functional targets relevant to epilepsy, and it calls for novel 
compounds with new mechanisms of action.   
 
In this work is detailed the synthesis of a 1,4-benzodiazepine as a new brain penetrant, 
selective, triple TTCC blocker. This new molecule is (3R,5S)-11 [(3R,5S)-N,1-dibenzyl-3,5-
dimethyl-1,2,3,5-tetrahydro-4H-pyrido-[3,4-e][1,4]diazepine-4-carboxamide]. Furthermore, 
Idorsia Pharmaceuticals characterized another promising molecule that reached clinical trials: N-
{1-[(5-cyanopyridin-2-yl)methyl]1H-pyrazol-3-yl}-2-{4-[1,1,1-(trifluoromethyl)cyclopropyl]-
phenyl}acetamide (12). Compound 12 (ACT-709478) is synthesised in this project by making 
react aminopyrazole 28 with 2-{4-[1,1,1-(trifluoromethyl)cyclopropyl]phenyl}acetic acid (24). 
Both compounds ((3R,5S)-11, 12) showed excellent efficacy on the WAG/Rij rat (Wistar 
Albino Glaxo from Rijswijk-rat) and GAERS (generalised absence epilepsy rat of Strasbourg) 
models, both genetic models of generalized epilepsy in rodent animals, demonstrating a strong 
decrease in the epileptic activity due to an excellent TTCC blockade.
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RESUM 
 
 L’epilèpsia representa una de les malalties cròniques del cervell més comunes afectant 
més de 50 milions de persones a tot el món. Els actuals fàrmacs antiepilèptics presenten 
múltiples mecanismes d’acció, ja siguin directes o indirectes, exercint la seva funció en la 
modulació de diversos canals iònics. Els canals més freqüents implicats són els receptors 
GABAA, els canals de sodi dependents de voltatge (VGSC), els canals de potassi voltatge 
dependents (VGKC), els canals de calci d’alt voltatge dependents (HVGCC) i el receptor AMPA. 
L’empresa farmacèutica Actelion es va proposar com a objectiu uns altres tipus de canals iònics: 
els canals de calci de tipus T (TTCCs), el llindar dels quals era baix, diferint així dels clàssics 
canals de calci d’alt voltatge. Aquests canals de baix llindar d’activació són producte de 
diferents gens presents als mamífers, essent així CACNA1H el més rellevant quant a 
epileptogènesi. Les epilèpsies no classificades són categoritzades com a “idiopàtiques” i existeix 
un fort enllaç entre la variació genètica del gen CACNA1H en els canals de calci tipus T i les 
epilèpsies generalitzades idiopàtiques (IGEs). Els diferents tipus de TTCCs són Cav3.1, Cav3.2 
(CACNA1H) i Cav3.3, el rol dels quals és crucial en l’excitabilitat neuronal i la contracció 
muscular. No obstant això, aquests antagonistes del calci han estat utilitzats tradicionalment 
per al tractament de malalties cardiovasculars i una optimització addicional de la seva pobra 
especificitat va portar una activitat biològica prometedora envers el canal Ca v3 pel tractament 
de l’epilèpsia. Actualment, hi ha aproximadament uns 28 AEDs disponibles comercialment per 
als pacients, malgrat això a causa dels processos fisiològics i fisiopatològics implicats en el 
procés de l’epilèpsia més del 30% d’aquests pacients epilèptics són fàrmacoresistents a la 
teràpia i, per aquest motiu, incapaços d’aconseguir un control de les convulsions. Tot i haver 
una sobreabundància de d’AEDs aprovats, hi ha una limitació de dianes funcionals rellevants 
per a l’epilèpsia i això requereix compostos novells nous amb mecanismes d’acció nous.  
 
En aquest treball la síntesi de 1,4-benzodiazepina està detallada com un nou compost, 
amb capacitat penetrant del cervell, selectiu i capaç de blocar els tres tipus de TTCCs. Es tracta 
de la molècula (3R,5S)-10 [(3R,5S)-N,1-dibenzil-3,5-dimetil-1,2,3,5-tetrahidro-4H-pirido-[3,4-
e][1,4]diazepina-4-carboxamida]. Addicionalment, l’empresa farmacèutica Idorsia va 
caracteritzar una altre molècula prometedora que va aconseguir arribar a assajos clínics: N-{1-
[(5-cianopiridina-2-il)metil]1H-pirazol-3-yl}-2-{4-[1,1,1-(trifluorometil)ciclopropil]-
fenil}acetamida (11). El compost 11 (ACT-709478) és sintetitzat en aquest projecte fent 
reaccionar l’aminopirazol 25 amb l’àcid 2-{4-[1,1,1-(trifluorometill)ciclopropil]fenil} acètic (23). 
Els dos compostos ((3R, 5S)-10, 11) van mostrar una eficàcia excel·lent en els models de 
ratolí WAG/Rij (Wistar Albino Glaxo de Rijswijk-rat) i GAERS (rata d’epilèpsia generalitzada  
d’Estrasburg), ambdós models d’epilèpsia generalitzada en animals rosegadors, demostrant així 
una forta disminució de l’activitat epilèptica a causa d’un excel·lent blocatge dels canals TTCC. 
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2. AREAS INCLUDED 
 
This undergraduate thesis encompasses the main subject, which is Organic Chemistry. 
At the end of this project, it is schematically shown one of the possible pathways to synthesise 
new compounds as potent T-type calcium channel blockers by organic reactions. This subject is 
concerned with carbon-like compounds in living organisms and nowadays extended to human-
made substances, chemical reactions and molecule properties. 
 
Another area included in this project is Molecular Biology, a field of science that has to 
do with the molecular basis, chemical structures and processes of biological phenomena as well 
as the regulation of different interactions. Since in this work it is explicitly explained how ion 
channels related to calcium work, the integration of this area becomes crucial to understand the 
mechanism of action of different antiepileptic drugs and newer molecules. 
 
This final degree project also covers Physiology and Pathophysiology due to the 
relevance of how epilepsy works and which processes of the organism change from normal 
conditions. Not only is essential for this reason but also for a good comprehension of how 
antiepileptic molecules exert their effect on different targets. While physiology is a medical 
discipline that describes normal functions, parts and processes of living organisms, 
pathophysiology is the study of a deranged role in an individual or an organ associated with a 
disease or syndrome. 
 
Last but not least, Pharmacology and Therapeutics is equally relevant to Organic 
Chemistry since both subjects represent the main fields of this project. Pharmacology is 
essential for the study of drug actions, drug discovery, their use and method of administration 
in the treatment of a disease. Therapeutics is more considered to be the science of healing that 
deals with the treatment of a disease. Taking into account that two new drug candidates for the 
treatment of epilepsy are going to be explained throughout this work, this last subject is 
notoriously indispensable to complete the project. 
3. INTRODUCTION 
Epilepsy can start at any age and affects millions of people worldwide. It is a complex 
brain disorder characterised by an abiding predisposition to generate epileptic seizures, which 
may present diverse phenotypes comprehending from a brief loss of consciousness or muscle 
spasms up to severe and extended convulsions. The term ‘epilepsy' should be considered as a 
set of diseases included in the nervous system that encompasses many seizure disorders and 
consequent syndromes that may be caused by various aetiologies. Clinical presentations and 
aetiologies are so diversified that the existing epileptic syndromes are classified in nearly 60 
different classes.  
 
The molecular basis of epilepsy is complex due to the numerous types of targets 
affected when epileptogenesis appears.  There is an increase of the neuronal excitability and a 
decrease of the inhibitory activity because the glutamate is more elevated, and GABA remains 
reduced. Since there is an increasing pharmacoresistance to the therapy even trying different 
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AEDs in combination, a new strategy has been assessed in clinical trials that consist of 
optimising calcium antagonists commonly used for hypertension and heart angina. On a first 
attempt, these drugs were added to the standard antiepileptic therapy using AEDs. However, it 
was later demonstrated that improving the properties of these cardiovascular molecules, drug 
metabolism and pharmacokinetics could show an excellent effect in epilepsy treatment by 
blocking T-type calcium channels.   
 
In this work, it is explained the link between these channels and how its inhibition 
enables a seizure suppression. After bibliographic research, I propose the synthesis of two 
promising antiepileptic molecules that have entered clinical trials. Researchers started from 
compounds with poor physicochemical and pharmacological properties, and by improving their 
solubility, lipophilicity and metabolic stability led to final molecules whose synthesis are 




The principal objective of this bibliographic project is to know the relation between 
calcium ion channels and their effect on epilepsy and to settle a synthetic pathway of two 
selected new compounds with promising effects on seizure suppression in epilepsy. Since the 
majority of calcium antagonists have been used for the treatment of cardiovascular diseases, in 
this work the aim is to know how a proper synthesis and molecule optimisation of a calcium 
channel blocker, is able to show high efficacy and optimum properties in generalised epilepsies. 
 
These hits selected for further optimisation, have been structurally similar to 
antihypertensive drugs, whose properties improvement led to new promising, brain penetrant, 
triple T-type calcium channel blockers and thus, became new candidates with new indications 
for epilepsy treatment. 
5. METHODS  
In this report, I propose a synthetic pathway to achieve new compounds with promising 
effects on the treatment of epilepsy. The synthesis has been possible due to the bibliographic 
research in scientific databases I have used. On the one hand, I have researched on the free 
platform PubMed®. Moreover another useful resource for my project it has been MEDLINE®, the 
National Library of Medicine® (NLM), the American Chemical Society® (ACS), the British Journal 
of Clinical Pharmacology® (BJCP) and the Epilepsy Foundation website. These platforms have 
provided the majority of bibliographic information; however, without a chemistry database like 
SciFinder®, it could not have been possible to develop this project since Organic Chemistry is 
the main covered area. This portal contains a huge database and literature from many scientific 
disciplines, which allows users to explore all properties and related information with chemical 
substances.  
 
Lastly, by using the ChemDraw® programme, I have been able to draw the chemical 
structure of all the explicit molecules in the project as well as their respective reactions 
depending on the section. 
   5
 
6. GENERAL FEATURES OF EPILEPSY 
6.1. Definition 
 
Epilepsy is defined as a neurological condition characterised by an enduring 
predisposition to generate recurrent seizures which may be unprovoked by any identifiable 
cause. An epileptic seizure is a brief episode of signs and/or symptoms caused by an unusual 
and excessive discharge of a set of neurons on the brain, and it ceases spontaneously1. 
Although the term ‘epilepsy’ is currently known as a single disease entity, it should be more 
considered as a symptom of a neurological disorder in the same manner for a seizure as a 
clinical manifestation2.  
 
Correctly defining the term of epilepsy, it is described as a set of diseases included in 
the nervous system caused by the alteration of the brain’s electrical activity provoking 
immediate symptoms and usually accompanied by losing consciousness.  Excessive neuronal 
hyperactivity causes adjacent transitory modifications of behaviour, perception or mobility. 
Symptoms may vary depending on the beam of affected neurons during the seizure2.  
 
Multiple, interacting factors contribute to the totality of epilepsy for an individual 
patient, for instance, a specific aetiology, genetic background, associated neurologic 
abnormalities, personality development and psychosocial adjustment, site of brain dysfunction, 
cognitive abilities, seizure activity, age of onset and duration as well as environmental factors3. 
 
6.2. Classification of epilepsies 
 
The International League Against Epilepsy (ILAE) is a worldwide organisation founded 
in 1909 whose goals are the advancement and dissemination of knowledge about epilepsy, the 
improvement services, care for patients and the promotion of research, education and training. 
This grouping managed to update classifications of seizures and epilepsies since previous terms 
were not as technical and precise as current ones. It limited clinicians and researchers to find 
an accurate care term to enhance communication and discussion and enable patients to 
understand their clinical condition4.  
 
Table 1. General classification and aetiology of epilepsies 












Combined generalised and 
focal 
Idiopathic (unknown) Unknown  
 
Since epilepsy is a disease that comprehends a collective of syndromes, there is a 
broader classification of epilepsies regarding its diverse clinical manifestation and the specific 
syndromes included in it (see Table 2). 
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Benign childhood epilepsy with 
centrotemporal spikes 
Childhood epilepsy with occipital paroxysms 
Primary reading epilepsy 
 
Symptomatic 
Chronic progressive epilepsia partialis 
continua of childhood 
Cryptogenic1 
The symptomatic and cryptogenic 
 categories constitute syndromes of wide 
individual variability that are based principally 
on: 
A. Seizure types 
B. Anatomic localisation 
 Temporal lobe epilepsies 
 Occipital lobe epilepsies 
 Frontal lobe epilepsies 
 Parietal lobe epilepsies 
Generalised 
Idiopathic 
 Benign myoclonic epilepsy in 
infancy 
 Childhood absence epilepsy 
(pyknolepsy) 
 Juvenile absence epilepsy 
 Juvenile myoclonic epilepsy 
 Epilepsy with grand mal (GTC) 
seizures on awaking  
 Other idiopathic generalised 
epilepsies not defined above 
 Epilepsies with seizures 
precipitated by specific modes 
of activation 
Cryptogenic or 
symptomatic (in order of 
age) 
West-syndrome (infantile spasms) 
Lennox-Gastaut syndrome 
Epilepsy with myoclonic-astatic seizures 
Epilepsy with myoclonic absences 
Symptomatic 
Nonspecific aetiology: 
 Early myoclonic encephalopathy 
 Early infantile epileptic 
encephalopathy with suppression-
burst 
 Other symptomatic generalised 
epilepsies not defined above 
Specific syndromes 
                                               
 
1Presumed to be symptomatic but with unknown aetiology. 
 




as to whether 
focal or 
generalised 
With both generalised and 
focal seizures 
 Neonatal seizures 
 Severe myoclonic epilepsy in infancy 
 Epilepsy with continuous spike-waves 
during sleep 
 Acquired epileptic aphasia (Landau-
Kleffner syndrome) 
 Other undetermined epilepsies not 
defined above 




 Febrile convulsions 
 Isolated seizures or isolated 
status epilepticus (SE) 
 Seizures due to acute 
metabolic or toxic factors such 




6.3. Classification of seizures 
 
Since seizures are one of the main clinical disorders of epilepsy and comprehend a vast 
manifestation depending on the person experiencing it, the ILAE managed to classify different 
types of seizures depending on the location of the brain disorder, muscular response and its 
origin. 
 
 Figure 1 ILAE 2017 classification of different seizure types4,5 
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6.4. Aetiology, physiology and pathology in epilepsy 
6.4.1. Aetiology 
 
The aetiology of this neurological disorder resides in multifactorial causes such as 
structural brain alterations with traumatic or non-traumatic antecedents for instance:  ictus, 
cranial trauma or brain tumour. Moreover, genomic mutations, immunological disorders and 
metabolic changes, like porphyria, may cause epilepsy as well. The most common cause of non-
genetic epilepsy is an infectious disease, which affects the brain; for example, brain tuberculosis 
or cysticercosis. Not only known disorders are the main responsible for causing the disease but 
also idiopathic causes are still highly prevalent in current diagnosis despite the diagnostic tests 
breakthroughs, leading to an undefined and unknown cause of the disease that difficult 
clinicians to establish a proper diagnostic6.  
 
The ILAE has defined six etiologic categories which are not hierarchically ordered and 
more than one might often apply4.  
 
1. Structural aetiology 
Seen by neuroimaging, an abnormal screening of an electroencephalogram (EEG) with 
discordant seizure semiology may suggest its starting point. Nevertheless, it is likely unrelated 
to the patient’s epilepsy and would not be considered relevant when classifying their epilepsy 
type3.  
 
2. Genetic aetiology 
Having a relevant family history and typical characters (seizure semiology, EEG) without 
the presence of molecular genetics is sufficient for a genetic aetiology classification. Thus, a 
specific variant in a gene or copy number variant, known to be pathogenic for epilepsy, would 
lead to a genetic cause. However, genetic disease-variants often arise de novo because of 
mutations and are not inherited, so despite a family history of epilepsy not always will a patient 
have a genetic cause for its epilepsy3. 
 
3. Infectious aetiology 
The usual cases of infectious epilepsy are caused by neurocysticercosis, human 
immunodeficiency virus (HIV), cytomegalovirus (CMV) and cerebral toxoplasmosis. Patients with 
seizures due to a resolved infection (e.g. meningitis) are classified as having an infectious cause 
of their epilepsy. Regarding non-resolved infections may be considered a structural aetiology as 
an acute infection3 provokes its seizures.  
 
4. Metabolic epilepsies 
A metabolic disorder can lead to an acute-symptomatic seizure (e.g. cerebral folate 
deficiency and pyridoxine-dependent seizures). Many metabolic epilepsies are genetic in terms 
of aetiology, as metabolic derangements mainly are inherited3. 
 
5. Immunaetiology  
Autoimmune disease is the leading cause of new-onset epilepsy (e.g. autoimmune 
encephalitis). There is proof that autoimmune encephalitis and epilepsy have been linked to 
both neuronal intracellular (GAD65, ANNA-1, and Ma) and neuronal cell surface antibodies 
(VGKC, NMDAR, AMPA, GABA-B, complex and GluR5)7,8. 
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6. Unknown category (idiopathic) 




Epileptic syndromes differ pathophysiologically despite sharing common ictogenesis 
features such as increased neuronal excitability and synchronicity, as well as mechanisms 
involved in interictal-ictal transition9. Alterations of synaptic functions and inherent properties of 
neurons are common mechanisms of hyperexcitability. Furthermore, due to molecular genetics 
research and progress, it has been pointed and hypothesis about mutations of genes encoding 
ion channels in some forms of human epilepsy9.  
 
Epileptic seizures arise from a sustained abnormal discharge of a group of neurons 
associated with a variety of causative factors such as trauma, neoplasms (e.g. Pleomorphic 
Xanthoastrocytoma, ganglioglioma, DNETs which are explained next below), infections, 
metabolic derangements, oxygen deprivation and inflammatory disorders of the cerebral 
hemispheres3. A neoplasm called Pleomorphic Xanthoastrocytoma is a superficially growing 
lesion with a meningeal component in young and middle-aged people10. Gangliogliomas are an 
admixture of neoplastic glial elements and disorganised cells including binucleate or 
multinucleate forms11. Regarding the acronym DNET, it stands for dysembrioplastic 
neuroepithelial tumour, a slow-growing glioneuronal neoplasm with a cortical or deep grey 
matter location that shows a powerful association with partial seizures12. An infection can cause 
a chronic inflammatory disorder, for instance, in the acute or chronic stages of herpes simplex 
encephalitis (HSE)8. However, the most common rare type of encephalitis designed to cause 
seizures is Rasmussen’s encephalitis, which appears as a juvenile form of epilepsy associated to 
a progressive neurologic deficit characterised by mental retardation and cognitive dysfunction8. 
Neuropathology of epilepsy depends on disorders of neuronal migration, genetic predisposition, 
spontaneous gene mutations and common structural defects of the brain9.  Ictogenesis is the 
generation of a seizure and arises from multiple non-specific causative factors. Reaffirming that 
distinct types of epilepsy differ in pathophysiology, numerous causes may originate neuronal 
hyperexcitability in ictogenesis9.  
 
Firstly, excitability arising from individual neurons happens in the post-synaptic 
membrane altering the character of receptor protein and thereby developing paroxysmal 
depolarisation. An increase of Ca+2 conductance takes place when epileptic neurons are 
activated9. Thus, the efficacy and the number of calcium channels is permanently increased. 
Secondly, not only individual neurons but also excitability from a neuronal microenvironment 
may cause ictogenesis as well. Functional and structural alterations occur at the same time in 
an epileptic seizure. Changes in neurotransmitter levels, concentrations of cations and anions 
and metabolic mutations involve both neurons and glia in structural changes9. For instance, 
excessive extracellular K+ depolarises neurons and leads to spike discharge. Thereby, changes 
in extracellular Ca+2 (decrease) during a seizure, precede those of K+ (increase), and calcium 
levels return to normal more quickly than K+  3.  
 
Different mechanisms are involved in interictal-ictal transition whether it is a 
nonsynaptic or synaptic mechanism3.  





1. Alterations in ionic microenvironment: some neurons are very sensitive to changes in 
membrane currents (e.g. increased extracellular K+, decreased extracellular Ca+2) 
2.  Decreases in the size of extracellular space  
3. Failure of ion transport:  Na+- K+ pump or Cl- - K+  co-transport 
4. Presynaptic terminal bursting 




1. Depression of GABAergic inhibition 
2. NMDA receptor activation, voltage-dependent EPSPs (excitatory postsynaptic potentials) 
3. Frequency potentiation of EPSPs 
4. Actions of modulations 
 
In terms of biochemistry, a seizure is provoked by an alteration of neurotransmitters 
due to the exaggerated hyperexcitability of neurons. Thereby, there is an inhibition of GABA 
A receptors and at the same time activation of glutamate receptors3,9. Metabolic pathways 
connect these two metabolites. In addition, the neuron sends the signal through voltage-
gated Na+/K+ ion channels that will arrive at the synaptic terminal where Na+ and Ca+2 
channels will be allocated leading to a positive potential membrane. Consequently, calcium 
will diffuse through ion channels and will provoke the release of neurotransmitters outside 
the terminal1,4.  
In order to stop seizures, a blockade of Na+ and/or Ca+2 ion channels and equilibration 
between both activator (enhance GABA activity) and inhibitory neurotransmitters (decrease 
glutamate activity) is a general strategy for epilepsy treatment3,13.  
 
6.5. Diagnostic tests  
 
Expecting a possible diagnosis of epilepsy, a medical evaluation may include a neurological 
exam and blood tests14. The most common tests used to diagnose epilepsy are mentioned 
below: 
 
x EEG (Electroencephalogram) 
EEG is a non-invasive and painless diagnostic that measures electrical impulses 
between brain cells. Electrodes are placed on the scalp, and the frequency of these 
impulses are measured and recorded on a graph. Any abnormalities on the brain waves 
can be used to identify the presence, location and severity of the seizures15,14. 
 
x MRI (Magnetic Resonance Imaging) 
A non-invasive diagnostic test that uses a magnetic field to measure changes in the 
brain. This technique provides detailed cross-sectional images that enable to detect any 
structural abnormalities, and it is considered to be the most important test when diagnosing 
                                               
 
2 Ephaptic interactions occur when currents from activated neurons excite adjacent neurons. 
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epilepsy because of its accurate brain representation. The procedure becomes invasive 
when contrast dye may be administrated to provide clearer images15,14. 
 
x fMRI (Functional MRI) 
Measures the changes in blood flow that occur when specific regions of the brain are 
working. It is commonly used before surgery to identify with precision the exact locations of 
critical functions (e.g. speech and movement) so that surgeons avoid any injuries in those 
regions while operating15,14. 
 
x SPECT (Single-Photon Emission Computed Tomography) 
This technique is based on imaging, whose purpose is to measure blood flow through 
the brain. A small amount of low-dose radioactive tracer is injected into a vein to create a 
detailed third-dimensions map of the blood flow activity in the brain during the seizures. 
SPECT is not usually necessary for diagnosing epilepsy15,14. 
 
x PET (Positron Emission Tomography) 
PET is an imaging technique that measures brain activity through its use of sugar and 
oxygen.  PET scans use a small amount of low-dose radioactive tracer which is injected into 
a vein and release tiny particles called positrons. This test helps to visualise active areas of 
the brain and detect abnormalities, and the data enable doctors to determine where the 
seizures occur15,14. 
 
x CTScan (Computed Axial Tomography) 
This technique is a non-invasive and painless test that produces cross-sectional images 
of different body areas using X-rays. CT scans reveal abnormalities in the brain that might 
be the cause of the seizure such as tumours, bleeding or cysts15,14. 
 
x MEG (Magnetoencephalography) 
A magnetoencephalography is a new test used to generate a representation of the 
brain's magnetic fields produced by brain activity. The aim is to identify potential areas of 
seizure onset15,14. 
 
7. ANTIEPILEPTIC DRUGS (AEDs) 
 
Around approximately 28 antiepileptic drugs are available to patients and have multiple 
targets. Despite the plenty of AEDs available and their use even in combination therapy, 
20-30% of epileptic patients are pharmacoresistant with seizures not appropriately 
controlled16. As knowledge on the pathophysiology of epilepsy, most mechanisms of action 
of AEDs are based on only a few and basic neurochemical mechanisms. Current AEDs 
decrease neuronal membrane excitability by interacting with ion channels or 
neurotransmitter receptor complexes17. Drugs that decrease membrane excitability through 
ion channels interactions act on sodium and calcium channels. Regarding AEDs that interact 
with neurotransmitter complexes, these can decrease the GABAergic activity by inhibiting its 
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7.1. Current approved AEDs and mechanism of action 
The current antiepileptic drugs available in the market are listed below including its 
chemical structure and classified by their primary mechanisms of action17. 
 
 
Enhance GABA action 
 
 
1. BENZODIAZEPINES (long-lasting 
effect) 
- Increase GABA action 




2. PHENOBARBITAL  
- Increases GABA action 
- Reduces sustained repetitive 
discharges 




3. PRIMIDONE (structural analogue of 
phenobarbital) 
- Reduces sustained repetitive 
discharges  










5. VIGABATRIN  
- GABA-Transaminase inhibitor 
- Inhibits GABA uptake 
 
 
6. GABOB (γ-amino-β-hydroxybutyric 
acid) 
- Analogue of the neurotransmitter 
GABA, may function as a 
neurotransmitter itself 
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7. PROGABIDE 
- GABA agonist at A and B sites 
 
 




- Blocks voltage-dependent Na+ 
channels 







- Inhibition of voltage-dependent Na+ 
channels 

















- Inactivates voltage-gated Na+2 
channels: decreases the sodium levels 
- Inhibition of glutamatergic 
neurotransmission (decreases NMDA 
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12. PHENYTOIN 
- Blocks voltage-gated Na+ channels 



























- Inhibition of glutamatergic activity. Is 
a selective non-competitive 
antagonist of AMPA receptors 
(ionotropic glutamate receptors) 
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17. LAMOTRIGINE 
- Reduces glutamate release 
- Inhibits voltage-activated Ca+2 









- Reduces T-type Ca+2 currents 





- GABA analogue but does not bind to 
GABA receptors 
- Increases synaptic GABA 
- May block amino acid transporter 
- Binds to voltage-dependent Ca+2 
channels reducing the intraneuronal 
concentration of calcium 






- Binds to voltage-dependent Ca+2 
channels reducing intraneuronal 
concentration of calcium 
  
 




- Is thought to stimulate synaptic 
vesicle protein 2A (SV2A), inhibiting 
neurotransmitter release  
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22. FELBAMATE 
- Inhibition of glutamatergic 
neurotransmission (decreases NMDA 
action, blocks glycine-site on NMDA 
receptor) 
- GABA potentiation 
- Blocks voltage-dependent Na+ 
channels 




23. VALPROIC ACID (VALPROATE) 
- Increases GABA levels by increased 
synthesis and reduced catabolism 
- Blocks T-type Ca+2 currents 





- Blocks Na+ channels 
- Blocks T-type Ca+2  channels  
- Increases GABA action 














- An allosteric modulator of KCNQ2-5 
(Kv7.2-7.5) ion channels. First 
neuronal potassium channel opener 




Most of AEDs have more than one mechanism of action, and its classification may vary 
depending on the pharmacological target. For instance, GABAA19 -receptors are targeted by 
benzodiazepines, voltage-gated Na+ channels by carbamazepine, lacosamide, lamotrigine, 
zonisamide and others; voltage-gated K+ channels by retigabine18 and high voltage-gated Ca+2 
channels by lamotrigine, levetiracetam, topiramate and others20,3,19. 
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8. CALCIUM CHANNEL BLOCKERS 
8.1. Voltage-gated calcium channels 
 
Calcium channels belong to the family of the voltage-gated channels as well as Na+, K+ 
and Cl- channels, which are permeable to this ions21. Aside from this group, it exists another 
type of channels called ligand-bound ion channels that include these channels but is activated 
by the extracellular presence of neurotransmitters such as glutamate, intracellular second 
messengers (e.g. Ca+2) or cyclic nucleotides (e. g. cAMP and cGMP21.  Most of these channels 
are allocated in the plasma membrane of all excitable cells, including the neurons of the 
peripheral and central nervous system22. Concretely, calcium channels are highly present in the 
dorsal root ganglia23. These channels control many critical physiological processes, and they 
allow the influx of calcium into the cytosol which leads to the regulation of several cellular 
processes like neuronal excitability, pain sensation, muscle contractions, cell development and 
proliferation and last but not least, hormone and neurotransmitter release16,23. 
 
Depending on the biophysical and pharmacological characteristics, calcium channels are 
classified into six different categories according to the required voltage range for their 
activation. Thus, the types of calcium channels discovered so far are called T, L, N, P, Q or R –
type channel24,3.  
 
Mainly, T-type calcium channels (TTCCs) are functionally distinct from other members 
of voltage-gated calcium channels (VGCCs) as possess a low voltage-activation25,23. In 
comparison to high voltage-activated (HVA) calcium channels, T-type channels have single-
channel conductance, fast activation and inactivation kinetic, hyperpolarised voltage-
dependences of activation and inactivation and slow deactivation kinetics26. 
 
TTCCs are defined by their alpha subunits encoding genes in the mammalian genome 
(e.g. CACNA1G yields to Cav3.1, CACNA1H to Cav3.2 and CACNA1I to Cav3.3)22. T-type calcium 
channels are mainly found in neurons, glial cells, fibroblasts, osteoblasts, retinal cells, 
adrenocortical cells as well as having a broad expression pattern including placenta, heart, 
kidney, smooth muscle, liver and the ovaries22. The Cav1 family encodes L-type calcium 
channels and includes different members (from Cav1.1 through Cav1.4)27. The Cav2 family 
comprehends Cav2.1, Cav2.2 and Cav2.3, which encode P/Q-type, N-type and R-type currents, 
respectively. On the other side, Cav3 includes the family of T-type channels with three 
subgroups (Cav3.1, Cav3.2 and Cav3.3)27.  
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8.2. T-type calcium channels (TTCC) and epilepsy 
 
Calcium T-channels are involved in the regulation of membrane potential and the 
control of intracellular calcium concentration24. In the brain, the three T-type calcium channel 
subtypes are broadly expressed and play a vital role in the regulation of neuronal excitability22. 
Concretely, TTCCs are located at the cortex (Cav3.1, Cav3.2), sensory thalamocortical neurons 
(Cav3.1) and reticular thalamic neurons (Cav3.2, Cav3.3)22. The different types of Ca+2 channel 
α-1 subunits are distributed within neurons, and due to the distinct functional properties, 
subcellular distributions and subunit composition have different physiological roles and play a 
major role as contributors to the development of seizures in epilepsy25. While P/Q-type channels 
contribute to generating absence seizures, T-type channels play a crucial role in idiopathic 
generalised epilepsies and pain28. The entry of Ca+2 ions through TTCCs leads to depolarization 
of the membrane and thus, generates low threshold spikes (LTS) in thalamic neurones (Cav3.2 
and Cav3.3 get involved)22. Thalamic neurons belong to a connected circuit that oscillates 
during natural processes but also can work at improper times as during a generalised seizure. 
The circuit is constituted by cortical neurons (glutamatergic), thalamocortical neurons 
(glutamatergic) and thalamic reticular neurons (nRT, GABAergic) and due to the unique voltage 
dependence of TTCCs allow them to generate low threshold spikes after a post-synaptic 
potential (inhibitory or excitatory)29. These channels remain inactivated at the resting 
membrane potential of many neurons and recover from an inactivation state during an 
inhibitory post-synaptic potential22. TTCCs open and close at negative membrane potentials and 
a large amount of Ca+2 entries through the channel to intracellular space leading to a high 
calcium concentration, especially in small compartments such as dendrities26. Another property 
of T-channels is the ability to generate “window currents” when the channel is available to be 
opened at a given potential instead of being inactivated22.  
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Calcium signalling plays a vital 
role in the survival of neurons, and it 
is crucial to understand that TTCCs 
are related to epilepsy because of 
their high expression in the 
thalamus25. There is a gene that is 
implicated in the susceptibility to 
develop epilepsy30. Idiopathic 
generalised epilepsies (IGE) are 
polygenic disorders caused by 
mutations of genes. CACNA1H and its 
functional variants are known to be 
associated with various generalised 
epilepsy syndromes31. Some variants 
of this gene are responsible for 
causing generalised absence 
epilepsies and studies on the Generalized Absence Epilepsy Rat of Strasbourg (GAERS) 
confirmed these variants are linked to seizure phenotype and can contribute to seizure 
susceptibility31. Pharmacological studies using genetic models of generalised nonconvulsive 
absence-like epilepsy (the generalised absence epilepsy rat of Strasbourg, GAERS, or the 
WAG/Rij rat models, Wistar Albino Glaxo from Rijswijk-rat) showed that TTCC blockers had 
strongly decreased the epileptic activity in these models24. Furthermore, mice overexpressing 
the Cav3.1 channels present recurrent spike-and-wave discharges whereas knockout mice 
lacking the Cav3.1 gene are protected from absence seizures24.  
 
Despite the progress in research about the role of calcium channels in epilepsy, there is 
not a precise mechanism that confirms how these variants increase seizure susceptibility. Some 
hypothesis predicted about TTCC variants that might cause changes in gating, and therefore 
epileptic seizures are: 1) changing the voltage-dependence of activation or inactivation, 2) 
accelerating channel opening, 3) decelerate channel inactivation, 4) slowing open to close 
transitions, 5) accelerating recovery and 6) increasing single channel conductance27. Many of 
these properties may be affected by CACNA1H variants found in IGE patients. Changes in the 
channel structure (e.g. variations on the different domains) may also play an important role in 
seizure susceptibility27.  
8.3. Molecular structure of calcium channel blockers 
 
T-type calcium channels are known to play roles in the development, preservation and 
repair of several tissues but also may cause disease when they are not adequately regulated. 
TTCC blockers have been established to treat several diseases, and the strongest point of these 
drugs is their safety as well as the efficacy25. Aside from their assigned clinical applications, 
recent studies have found a powerful neuroprotective effect of T-type calcium channel blockers 
and a useful effect in treating many neurological diseases in animal models25.  
8.3.1. Clinically used AEDs that act on T-type calcium channels 
 
Calcium channels can be modified by many antiepileptic drugs such as ethosuximide, 
zonisamide, valproate, phenytoin (see Figure 4), mibefradil (see Figure 6) and others. This last 
one was withdrawn from the clinical market in 1998 due to drug interactions leading to 
abnormal heart rhythms25. Regarding to its structure, ethosuximide is a succinimide and it has 
Figure 3. Distribution of low-voltage-gated TTCCs in 
the brain21  
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been used for the treatment of absence seizures (generalised nonconvulsive pattern) while 
zonisamide is chemically classified as a sulphonamide and is used to treat partial seizures, 
childhood epilepsy and other types of convulsions. These two drugs reach therapeutic 
concentrations to block the T-type calcium channels and show neuroprotection aswell25. 
 
 
Figure 4. Examples of four antiepileptic TTCC blockers 
 
 
Compared to other AEDs, valproate has a very different structure with an achiral short 
branched fatty acid with eight carbons that does not include nitrogen or a cyclic ring25. 
Phenytoin (see Figure 4) shows the chemical structure of a diphenylimidazolidinedione. In like 
manner, many antihypertensive/antianginal CCBs where thought to be useful in epilepsy due to 
its L-type Ca+2 channel blockade25. Nevertheless, amongst all clinically relevant CCBs to treat 
cardiovascular disorders, the majority of them are usually able to block both L-type and T-type 
calcium channel25. Dihydropiridines32, phenylakyilamines33 and benzothiazepines25 are the three 
separate classes of this antihypertensive TTCC blockers drugs. 
 
Figure 5. General structure of antihypertensive TTCC blockers 
 
 
Various antihypertensive/antianginal drugs have clinically assessed as new antiepileptic 
molecules. Comparing the IC50 values between Table 3 and Table 4, there is proof that some of 
these cardiovascular drugs can block T-type calcium channels in the same threshold than some 
classical antiepileptic drugs (e.g. ethosuximide and zonisamide in Table 3). Zonisamide has a 
similar IC50 to azelnidipine, aranidipine and less resemble amlodipine values. However, bearing 
in mind that both types of drugs can block TTCC at similar ranges, the next step to optimize 
these cardiovascular molecules to enter next clinical trials phases is to prove its metabolic 
stability in liver microsomes, in vivo brain penetration, unbound fraction in plasma and brain, 
animal model testing, pharmacokinetics in the rat and further studies required24. 
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Table 3. Data of the TTCC inhibition of two antiepileptic drugs25 








MW (g/mol) 141.17 212.23 
IC50 (mM) TTCC 0.3-1.0 0.05-0.5 
 
 
Here below are listed different dihydropyridines being assessed in various countries as new 
antiepileptic drugs. Some of them have already been approved by the Food and Drug 
Administration (FDA) in several countries25. 
 
 Figure 6. Dihydropyridines and Mibefradil tested as antiepileptic drugs 
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Table 4. Antihypertensives/antiangina25 
Drug Pathways inhibited MW (g/mol) IC50 (mM) TTCC 
Amlodipine T-type (Cav3.2 > 
Cav3.1 or Cav3.3), L-
type; Na; K 
408.88 0.031 
Aranidipinea CJ T-type and L-type 388.37 0.03-0.04 
Azelnidipinea  CJ T-type and L-type 582.65 0.04-0.07 
Barnidipinea SJO T-type and L-type 528 0.005-0.02 
Benidipinea IJCO T-type and L-type 542.02 0.003-0.2 
Efonidipinea J T-type and L-type 631.66 0.0029 
Mibefradila O T-type and L-type; 
Na; K 
568.55 0.00017-0.00029 
Nicardipine T-type and L-type 515.99 0.0028 
Nimodipine T-type and L-type 418.44 0.0056 
J Japan, C China, I India, S Spain, O other, MW Molecular Weight 
a Not currently Food and Drug Administration (FDA) approved 
 
 
Observing the data in the previous tables (Table 3 and Table 4) provided by a review 
from the European Journal of Physiology25, there is proof that dihydropyridines used 
traditionally as antihypertensive agents can block TTCC with results of IC50 similar to traditional 
antiepileptic drugs. For instance, amlodipine (IC50 0.031), aranidipine (IC50 0.03-0.04) and 
azelnidipine (IC50 0.04-0.07) show a nearby IC50 value of blockade as ethosuximide (0.3-1.0).  
8.3.2. Novel T-type calcium channel antagonists 
 
Inhibition of T-type calcium channels could be useful for the treatment of several 
central or peripheral diseases like pain, oncology, sleep disorders, Parkinson’s disease or 
epilepsy24 as well as playing an important role in neuroprotection25. Since pharmacoresistance 
to AEDs even in combination treatment is currently increasing20, this calls for new compounds 
with new mechanisms of action. Especially, low-voltage-gated T-type calcium channels which 
are being assessed in several clinical trials20. First molecules discovered that claimed to be new 
TTCC blockers were Mibefradil (1) (currently withdrawn from the market)34,20,24, Z-941 (2) and 
Z-944 (3), discovered by Epirus Biopharmaceuticals, are a piperidine-like molecule that showed 
efficacy in rodent models of seizure)24,34,35, MK-8998 (4), finally assigned for the treatment of 
acute psychosis in patients with schizophrenia)24,34,35, ABT-639 (5, finally suitable for the 
treatment of diabetic neuropathies)24, TTA-P1 (6) and TTA-P2 (7), discovered by Merck 
Pharmaceuticals, has a piperidine-like molecular structure with good brain penetrance and 
suppression of seizures in the WAG/Rij rat model)22 and TTA-A2 (8), identified by Merck, is the 
amide analogue of TTA-P compounds)22. 
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On the one side, Actelion Pharmaceuticals identified a compound with a 
dihydropyrazole structure starting with the development of high-throughput FLIPR assays using 
similar conditions to other assays against three subtypes of Cav3 channels published previously. 
Optimisation of this molecule led to a series of dihydropyrazole compounds as potent, selective 
and brain penetrant TTCC blockers as well as having a good profile on cardiovascular safety 
(e.g. less hypotension as a side effect)35. Concretely, dihydropyrazole 9, was used to evaluate 
potential efficacy and minimal safety issues35. However, issues related to solubility and 
intellectual property led to stop the development of this class of compounds35. Another attempt 
was the identification of new 1,4-benzodiazepines as brain penetrant and selective triple TTCC 
blockers. Starting from high-throughput screening (HTS) hit 10 with poor physicochemical and 
in vitro drug metabolism and pharmacokinetics (DMPK) properties of the molecule24, they 
established a clear structure-activity relationship (SAR) to identify moieties allowing the 
improvement of its chemical properties. Optimisation led to the preparation of pyridodiazepine, 





















 TTA-P1 6 
 
 
 TTA-P2 7 
 
 
 TTA-A2 8 
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On the other side, Idorsia Pharmaceuticals discovered compound 12 (ACT-709478)34, 
which has been selected as a clinical candidate, starting from the optimisation of derivatives 














8.3.2.1. Synthesis of compound (3R,5S)-8: a promising, efficient triple T-type 
calcium channel blocker 
 
Actelion Pharmaceuticals have recently used a FLIPR assay within a HTS campaign24 
that led to the identification of a compound which was crucial for the discovery of (3R,5S)-11 
hit. This compound 10 showed a poor solubility profile, high lipophilicity and low metabolic 
stability24. The aim of their study was the maximum optimisation of this compound improving 
its pharmacokinetic profile based on changing different moieties of the original molecule. 
Different pathways of synthesis and its final products were compared in terms of biological 
activity on Cav3.1, Cav3.2, Cav3.3, solubility and brain penetration, which is measured by 
lipophilicity24. Final molecule (3R,5S)-11 resulted highly effective in the WAG/Rij-rat model of 
generalised non-convulsive absence-like epilepsy24. 
 
The first molecule 10 used as a hit to improve its properties was synthesised by the 
classical amide coupling-cyclization-reduction strategy24. Unfortunately, a non-benzodiazepine 
pyridine core was less potent and promising than a pyridodiazepinic core-like molecule24. Thus, 
another approach to reach the final molecule was an aromatic nucleophilic substitution (SNAr) 
which was a 6 step sequence24. The synthesis of derivative 11 reported as an example, started 
reacting both commercial 3-fluoroisonicotinonitrile (13), primary amine 14 and triethylamine in 
NMP stirred at 90 ºC overnight, leading to pyridine 1524. Water was added to the reaction 
mixture at room temperature and the precipitate was filtered and washed with water24. The 
solid was dissolved in DCM and washed again with water24. The organic layer was separated, 
dried in MgSO4, filtered and further purified to give a white-like solid24. The solvents are usually 
removed under reduced pressure so that the pureness of the compound is optimised. 
Compounds number 13 and 14 can also be prepared with different reagents although being 
commercially available. Compound 15 was treated with MeLi in THF at a temperature of 0 ºC 
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and, posteriorly, settled to room temperature overnight24. This reaction, which had medium 
output, led to a methylketone 16 (Scheme 1)24.  
 
Scheme 1. Synthesis of the Benzodiazepine Pyridine Core (SNAR strategy) 
 
 
To the solution of (±)-tert-butyl-(1-((4-acetylpyridin-3-yl)amino)-propan-2-yl)carbamate 
(16) was added 4M HCl in dioxane and the solution was stirred at rt overnight until the Boc 
deprotection was completed, achieving compound rac-1736. The imine molecule was 
subsequently benzylated on the anilic nitrogen using benzylbromide in DMF and NaH as a base 
during 2h at 70 ºC, the reaction had a 60% output and turned out to molecule 18 (Scheme 
2)24. Firstly, NaH was stirred at 0 ºC in DMF to a stirred solution of 17, and secondly, after a 20 
min stirring at 0 ºC, benzylbromide was added at 70 ºC for 2 hours36. The aqueous layer was 
adjusted to pH 10-11 and extracted with EtOAc. The organic phase was dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified as a yellow oil to 
give (±)-1-benzyl-3,5-dimethyl-2,3-dihydro-1H-pyrido[3,4-e][1,4]diazepine (18)36. 
 
Scheme 2. Boc deprotection and benzylation 
 
 
In order to reach compound 19, imine 18 was hydrogenated with the presence of the 
catalyst Pd/C, mixed in a solution with MeOH, stirred at room temperature during 1.5h and 
finally yielded 19, a cis/trans compound with diastereoselectivity of 9:124. The reaction had a 
77% of output and the residue, once purified, gave cis-19 after a column chromatography was 
used to separate both diastereoisomers. Compound cis-19 was submitted to urea formation by 
adding benzyl isocyanate (BnNCO) and DIPEA at standard conditions overnight to achieve 
molecule 20, which showed a high output of 80% (Scheme 3)24. The output of the reaction 
was 80%, and the residue was purified to yield (3R,5S)-1136. 
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To obtain the optimum enantiomer of molecule 20, a chiral HPLC took place in order to 
separate (3R,5S)-11 from (3S,5R)-11, whose appearance is presented as white solids. The 
effect of the inhibition on TTCC of both enantiomers is shown on the table below in terms of 
half maximal inhibitory concentration (IC50)24.  
 
Table 5. Activities of the enantiomers of molecule 1124 
  
Cav3.1 IC50 = 138 ± 5 nM (n=3) Cav3.1 IC50 = > 10000 nM (n=3) 
Cav3.2 IC50 = 132 ± 36 nM (n=3) Cav3.2 IC50 = > 11000 nM (n=3) 
Cav3.3 IC50 = 11 ± 1 nM (n=3) Cav3.3 IC50 = > 10000 nM (n=3) 
HLM (μL/min/mg) = 56 (n=1) 
RLM (μL/min/mg) = 1156 (n=1) 
 
 
From compound number 20 until the discovery of the appropriated enantiomer as a 
clinical candidate, physicochemical properties were improved and in vitro DMPK were assessed 
in the WAG/Rij-rat model (generalised non-convulsive, absence-like epilepsy). Compound 20 
was selected as a lead candidate and it displayed good solubility, improved HLM stability, 
moderate penetration of blood-brain barrier (BBB), unstable in terms of RLM and high exposure 
in plasma (Cmax) after a pharmacokinetic in vivo study performed in WAG/Rij rat-model at a 
high dose of 100 mg/kg po. Moreover, a brain free fraction was calculated into brain 
concentration, and it corresponded approximately 0.25 times, 0.15 times, and 1.5 times the 
IC50 on the human Cav 3.1, Cav 3.2, and Cav 3.3 channels. Brain exposure may not be its 
strongest point, especially in Cav 3.1 and Cav 3.2 subtypes; however, molecule 20 was selected 
for proving its in vivo efficacy in the WAG/Rij-rat model of generalised non-convulsive absence-
like epilepsy24.  
 
Molecule 11 was selected for a preparative chiral HPLC to increase the probability of in 
vivo efficacy24. Derivative (3R, 5S)-11 was two times more active and stable in human liver 
microsomes (HLM) in comparison to rac-11. At the single oral dose mentioned before, these 
rats showed a decrease of  50% regarding the number of seizures and duration of them24. This 
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study performed by Actelion Pharmaceuticals used telemetric transmitters which allowed a 
recording of the EEG24. To sum up, after SAR studies, in vivo pharmacological studies and 
DMPK properties, starting from the hit number 10 an improved molecule was discovered 
(3R,5S)-11 showing a strong efficacy in the Cav3.3 T-type calcium channel (10 times stronger 
than Cav3.1 and Cav3.2)24. This results underline the importance and implication of this channel 
subtype in the pathophysiology of generalised epilepsies and suggest that the different channel 
variants in epilepsy would need a selective compound for one or the other T-type calcium 
channel subtypes24. 
8.3.2.2. Synthesis of compound ACT-709478: a new clinical candidate 
 
Idorsia Pharmaceuticals reported the discovery of a new class selective, potent, brain 
penetrant T-type calcium channel blocker with a pyrazole carboxamide structure. One of the 
requirements for this molecule was an Ames negative result in the Ames test, which is 
biological assay used to identify revert mutations present in strains, substances34,37, etc. by 
using bacteria to test whether a given chemical can give variations in the DNA of the test 
organism. Firstly, compound 28 (see Scheme 6) was identified as an Ames-negative 
aminopyrazole and was selected as a candidate to react with other successful compounds34 and 
achieve an optimum molecule. After final optimisation, compound 24 (see Scheme 5) was 
identified and finally entered phase l clinical trials.  
 
As shown in Scheme 4, tert-Butyl 2-{4-[1,1,1-(trifluoromethyl)cyclopropyl]phenyl}-
acetate (23), is obtained by a mixture of 1-bromo-4-[1,1,1-(trifluoromethyl)-
cyclopropyl]benzene (21), 2-tert-butoxy-2-oxoethyl-zinc chloride (22), Pd3(dba)3 and X-PHOS 
in THF at room temperature and stirred overnight at 90 ºC34. The reaction had an output of 
96%. Moreover, another pathway to obtain compound 23 is using the commercially available 
product. 
 




To obtain carboxylic acid 24, one of the main reagents, a solution of compound 23 is 
mixed with HCOOH at room temperature overnight (Scheme 5)34. As usual in these 
experimental sections, solvents are removed under reduced pressure.  
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In order to synthesise molecule 28, K2CO3, and Bu4NBr in acetone were added into a 
mixture of 6-bromomethylnicotinonitrile (25) and 5-nitro-1H-pyrazole (26)  at rt during 2.5 h. 
The reaction showed an output of 63% (Scheme 6)34. The resulting product 27 was filtered and 
rinsed with acetone and further purified by automated flash chromatography34. To a mixture of 
the resulting product, reagents Fe and NH4Cl were added, and the mixture was heated at 75 ºC 
during 1.5 hours34. After cooling down at room temperature and yielding a 95%, molecule 28 
was formed (Scheme 6)34.  
 





Finally, compound 24 and 28 were added into a mixture of CH3CN, DIPEA and HATU, 
yielding a 58% (Scheme 7)34 and leading to a final compound named ACT-709478 (12) The 
solution was stirred overnight, and the solvents were removed under reduced pressure34.  
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The selectivity of this aminopyrazole (12) was evaluated against a wide human cardiac 
and neuronal ion channels where calcium channels are implicated, showing an inhibitory effect 
of compound 12 on currents through hCav3 type and a negative Ames test34. This compound 
was tested in mice, dog and cynomolgus TTCCs and showed a good blockade of Cav3.3 
channels but with marked voltage-dependency34. It also blocked other calcium channels such as 
1.2, 1.3 and 2.1 but with less potency34. The potential of compound 12 to cause drug 
interactions were evaluated by studying the inhibition of P-450 cytochrome and the inhibition 
potential of 12 was predicted to be low34. Referring to DMPK studies, PK of molecule 12 was 
assessed by predicting the clearance from microsomes (rat and human liver microsomes)34. 
Thus, the approach for a prediction of the human clearance in man was estimated, and both 
extrapolated clearance from HLM as well as RLM resulted in a low predicted clearance of 
compound ACT-70947834. Consequently, these results made the compound a new suitable 
candidate antiepileptic drug as a TTCC blocker. 
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9. CONCLUSIONS 
Despite the numerous antiepileptic drugs currently available, it remains a wide 
resistance to the therapy of epilepsy. Increasing evidence from various studies indicates that T-
type Ca+2 channels play a crucial role in neuronal excitability that underlies seizures. Bearing in 
mind that most of AEDs are seizure suppressors instead of being both seizure inhibitors and 
anti-epileptogenic, it urges to develop new compounds with high specificity on the different 
types of calcium channels (Cav3.1, Cav3.2 and Cav3.3).  
 
Firstly, two main compounds have been synthesised along the project whose 
therapeutic effect is improved towards the actual AEDs. Both are calcium antagonists. Since the 
three types of Ca+2 channels are widely expressed in the brain, these newer compounds act in a 
specific way, not only blocking the three of them but also showing a certain tendency to block 
one concretely. These molecules have reached Phase I clinical trials due to its potency, 
specificity and safety regarding to epilepsy treatment.  
 
Secondly, whether the epilepsy is genetic or acquired, these new molecules have 
demonstrated in in vivo studies in animal models an excellent efficacy on the TTCC blockade. 
According to the predicted effect on human, researchers from Actelion Pharmaceuticals and 
Idorsia Pharmaceuticals, extrapolated data from the animal models and thus, results obtained 
were promising for becoming new candidates in epilepsy treatment. Molecule (3S,5R)-11 
discovered by Actelion Pharmaceuticals was obtained from optimisation of a hit with poor 
physicochemical and DMPK properties. In recent studies, the racemic mixture of molecule 11 
showed excellent HLM stability and thus, was elected for in vivo efficacy studies. The separation 
of the racemic mixture by chiral HPLC demonstrated the difference between both enantiomer 
properties, being (3S,5R)-11 the most suitable compound for further investigation. Regarding 
to specificity, this pyridodiazepine showed modest activity on Cav3.1, Cav3.2 while Cav3.3 was 
strongly blocked on the WAG/Rij rat model, highlighting the importance and implication of 
Cav3.3 in the pathophysiology of generalised epilepsies. 
 
Thirdly, molecule 12 was obtained by Idorsia Pharmaceuticals and displayed excellent 
properties allowing this aminopyrazole to enter phase I clinical trials. By making react two final 
molecules 24 and 28 in specific conditions and reagents, compound ACT-709478 was finally 
obtained. In the same manner as molecule (3S,5R)-11, metabolic stability in liver microsomes 
was studied as well as the unbound fraction in plasma, pharmacokinetics, in vivo brain 
penetration potential, drug interaction and other safety studies. Different classes of TTCC were 
studied and, in comparison to Actelion Pharmaceuticals whose purpose was to identify a 
substance capable of blocking one specific Ca+2 channel, Idorsia Pharmaceuticals wanted to 
develop a molecule blocking all three TTCCs with minimal divergences between their potencies.  
 
Finally, the implication of TTCCs in many diseases led to a need to identify truly selective 
TTCC antagonists. In epilepsy, the overexpression of these channels contributes to a high 
predisposition to epileptogenesis. This fact suggested a new drug discovery programme on 
novel, potent and more selective TTCCBs used in cardiovascular diseases and now approached 
to the epilepsy field. These two molecules became promising clinical candidates for a new 
strategy on generalised epilepsy treatment. 
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